)
Edge15 May 2026
TOMRA: Closing the Loop
The story of TOMRA: from reverse vending machine pioneer to global technology for deposit systems, recycling, and resource optimization.
Autolus Therapeutics
Autolus Therapeutics (AUTL) investor relations material
Autolus Therapeutics Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2026 earnings summary14 May, 2026
Executive summary
Q1 2026 net product revenue reached $26.2 million, up from $9.0 million year-over-year, driven by strong AUCATZYL launches in the US and UK, with positive physician feedback and expanding patient demographics.
Achieved first positive gross margin for the ALL business, supported by increased volume, operational improvements, and cost reduction initiatives.
Strategic operational efficiency plan included a 13% workforce reduction, expected to save $15 million annually starting in 2027.
Pipeline progress includes ongoing pivotal and early-stage trials in pediatric ALL, lupus nephritis, progressive MS, and light-chain amyloidosis, with key data readouts expected through 2028.
Financial highlights
Net product revenue for Q1 2026 was $26.2 million, up from $9.0 million in Q1 2025, reflecting US growth and initial UK sales.
Positive gross margin of $1.6 million in Q1 2026, compared to losses in prior quarters.
Cost of sales increased to $24.6 million, mainly due to higher sales volume and inventory-related costs.
R&D expenses decreased to $21.2 million, while SG&A expenses rose to $39.9 million, partly due to one-time restructuring costs.
Net loss for Q1 2026 was $71.6 million, or $(0.27) per share, slightly higher than $70.2 million, or $(0.26) per share, in Q1 2025.
Cash, cash equivalents, and marketable securities totaled $229.4 million at March 31, 2026, down from $300.7 million at year-end 2025.
Outlook and guidance
Full-year 2026 AUCATZYL net product revenue guidance remains $120 million–$135 million, unchanged from prior forecasts.
Continued positive gross margin anticipated for 2026, with peak gross margin targeted at 65%-70%.
Cash runway projected into Q4 2027 based on current plans and revenue expectations.
Profitability for the ALL business anticipated in 2028, with company-wide profitability dependent on reinvestment rates.
No EU product revenue expected in 2026 as commercial launch in Germany and other EU countries is on hold.
Annualized savings from the strategic initiative
BOBCAT trial data reporting schedule
ROCCA registry coverage of US commercial patients
Cellares feasibility and scaling for MS
Rationale for excluding Blincyto as bridging
BOBCAT year-end success metrics
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Autolus Therapeutics
- 2025 revenue reached $74.3M; 2026 guidance is $120–$135M with positive gross margin expected.AUTL
Q4 202514 May 2026 - AUCATZYL shows high efficacy and safety, driving growth and broader access in ALL therapy.AUTL25th Annual Needham Virtual Healthcare Conference13 Apr 2026
- AUCATZYL drives revenue and clinical success, with pipeline growth in oncology and autoimmune diseases.AUTLCorporate presentation13 Apr 2026
- Shelf registration enables up to $150M in securities to fund T cell therapy growth and expansion.AUTLRegistration filing13 Apr 2026
- Major shareholders are reselling 54.6M ADSs; company receives proceeds only from warrant exercises.AUTLRegistration filing13 Apr 2026
- Obe-cel achieves high efficacy and safety, supporting expanded use in frontline and pediatric ALL.AUTLStatus update13 Apr 2026
- Rapid market leadership and expansion into new indications drive strong growth outlook.AUTLTD Cowen 46th Annual Health Care Conference3 Mar 2026
- Obe-cel demonstrates durable survival and safety in ALL, with launch and financial readiness secured.AUTLGoldman Sachs 45th Annual Global Healthcare Conference3 Feb 2026
- Obe-cel nears FDA decision with strong data, cash reserves, and US launch readiness.AUTLQ2 20242 Feb 2026
Next Autolus Therapeutics earnings date
Q2 20266 Aug, 2026
Autolus Therapeutics
Next Autolus Therapeutics earnings date
Q2 20266 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage